Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Column

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs
Clinical Pathways GPS
Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs
04/21/2020
Matthew Pakizegee, PharmD, MS
Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Craig Ornstein, PhD, MA
Uttama Rath, PhD, MS
Jamey Hardesty, MPH
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
...
04/21/2020
Journal of Clinical Pathways
Real-World Data Analysis and Considerations for Use
Editor's Page
Real-World Data Analysis and Considerations for Use
03/16/2020
Winston Wong, PharmD, Editor-in-Chief
Google the question “what is real-world evidence.” One of the first citations will be a link to the Food and Drug Administration (FDA) page defining both real-world evidence (RWE) and real-world data (RWD). The FDA...
Google the question “what is real-world evidence.” One of the first citations will be a link to the Food and Drug Administration (FDA) page defining both real-world evidence (RWE) and real-world data (RWD). The FDA...
Google...
03/16/2020
Journal of Clinical Pathways

Advertisement

Financial Advocacy Network: Hub for Education, Resources, and Peer-to-Peer Learning
Trending From ACCC
Financial Advocacy Network: Hub for Education, Resources, and Peer-to-Peer Learning
03/16/2020
JCP Editors
Over the past decade, the field of oncology has seen remarkable advances stemming from a better understanding of the molecular biology of many cancer types. This growing body of knowledge has led to improvements in...
Over the past decade, the field of oncology has seen remarkable advances stemming from a better understanding of the molecular biology of many cancer types. This growing body of knowledge has led to improvements in...
Over...
03/16/2020
Journal of Clinical Pathways
Where Incentives Align (or Don’t) Among Health Care Stakeholders and How They Are Evolving
Pharma Insights
Where Incentives Align (or Don’t) Among Health Care Stakeholders and How They Are Evolving
03/16/2020
Avi Mamidi, PharmD
Elizabeth Oyekan, PharmD, FCSHP, CPHQ
Jeremy Schafer, PharmD, MBA
Larry Blandford, PharmD—Column Editor
The goal of all health care stakeholders—payers, providers, and health systems—is to lower health care costs and improve patient health outcomes, yet the path to getting to this goal remains questionable, partially...
The goal of all health care stakeholders—payers, providers, and health systems—is to lower health care costs and improve patient health outcomes, yet the path to getting to this goal remains questionable, partially...
The...
03/16/2020
Journal of Clinical Pathways
Building Episodes of Care Models for Oncology & Other Chronic Conditions
Engaging Payers
Building Episodes of Care Models for Oncology & Other Chronic Conditions
03/16/2020
Lili Brillstein, MPH—Column Editor
The episodes of care payment model is designed to put the patient at the center of care delivery, with their care coordinated among all providers for more comprehensive care to achieve the best possible outcomes....
The episodes of care payment model is designed to put the patient at the center of care delivery, with their care coordinated among all providers for more comprehensive care to achieve the best possible outcomes....
The...
03/16/2020
Journal of Clinical Pathways

Advertisement

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease
Clinical Pathways GPS
Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease
03/16/2020
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Matthew Pakizegee, PharmD, MS
Jonathan W Hodgson, MBA
Chad McAuliffe
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...
...
03/16/2020
Journal of Clinical Pathways
Real-World Use of Value-Based Tools and Tracking Outcomes
Editor's Page
Real-World Use of Value-Based Tools and Tracking Outcomes
02/18/2020
Winston Wong, PharmD, Editor-in-Chief
High-quality tools have the ability to utilize sophisticated digital mechanisms to improve patient outcomes while also enhancing data collection, lowering costs, and increasing accountability. Clinical pathways and...
High-quality tools have the ability to utilize sophisticated digital mechanisms to improve patient outcomes while also enhancing data collection, lowering costs, and increasing accountability. Clinical pathways and...
...
02/18/2020
Journal of Clinical Pathways
2019 ACCC Survey Respondents Recognize Care Standardization as Opportunity for Cost Savings
Trending From ACCC
2019 ACCC Survey Respondents Recognize Care Standardization as Opportunity for Cost Savings
02/18/2020
JCP Editors
In January, the Association of Community Cancer Centers (ACCC) released results of the “2019 Trending Now in Cancer Care Survey.” This marks the 10th year of the annual ACCC survey, which is designed to identify...
In January, the Association of Community Cancer Centers (ACCC) released results of the “2019 Trending Now in Cancer Care Survey.” This marks the 10th year of the annual ACCC survey, which is designed to identify...
In...
02/18/2020
Journal of Clinical Pathways

Advertisement

Where Will Health Care Take Us in the 2020s?
Pharma Insights
Where Will Health Care Take Us in the 2020s?
02/18/2020
David Carr, PhD
Larry Blandford, PharmD—Column Editor
As we say goodbye to the 2010s, we look at the prevailing trends and project forward to what we think are the key topics to consider in the coming decade—not an easy task. Looking back at commentary and predictions...
As we say goodbye to the 2010s, we look at the prevailing trends and project forward to what we think are the key topics to consider in the coming decade—not an easy task. Looking back at commentary and predictions...
As we...
02/18/2020
Journal of Clinical Pathways
Clinical Pathways and Policy to Guard Against Misaligned Incentives
Clinical Pathways GPS
Clinical Pathways and Policy to Guard Against Misaligned Incentives
02/18/2020
Mathew Pakizegee, PharmD, MS
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Seth Gordon, MBA
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization...
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization...
The...
02/18/2020
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use